

Original Article**Genotyping of peroxisome proliferator-activated receptor gamma (PPAR- $\gamma$ ) polymorphism (Pro12Ala) in Iranian population***Fatemeh Namvaran<sup>a,b</sup>, Parvaneh Rahimi-Moghaddam<sup>a</sup>, Negar Azarpira<sup>\*b</sup>,***Abstract**

**BACKGROUND:** The peroxisome proliferator-activated receptor- $\gamma$  (PPAR- $\gamma$ ) is a nuclear hormone receptor. It is predominantly expressed in adipose tissue and as a receptor for thiazolidinediones, it has drawn attentions towards itself as a key molecule to trigger pathways involving in some diseases such as cancers, type 2 diabetes, inflammations and osteoporosis. A proline changed to alanine in codon 12 of PPAR- $\gamma$  gene (Pro12Ala) has been known to be responsible for decreased risk of type 2 diabetes. The aim of the present study is to investigate the frequency of Pro12Ala polymorphism in PPAR- $\gamma$  in healthy Iranian population to compare with other populations. Understanding this polymorphism may help us in better diagnosis, prevention, and therapeutic approaches toward a better management of diseases such as type 2 diabetes and osteoporosis.

**METHODS:** 128 healthy volunteers were enrolled in this study. To determine single nucleotide polymorphisms (SNPs), we did real time polymerase chain reaction (RT-PCR), using TaqMan allelic discrimination assays.

**RESULTS:** Genotype frequencies for PPAR- $\gamma$  gene Pro12Ala (rs1801282) polymorphism were 0.86 for CC, 0.14 for CG, 0.00 for GG while allelic frequencies were 0.93 and 0.07 for C and G, respectively.

**CONCLUSIONS:** There are statistical differences between the distribution of the PPAR- $\gamma$ -2 Pro12Ala polymorphism in other populations and Iranian population.

**KEYWORDS:** PPAR Gamma, Polymorphism, Genetic, Iran.

JRMS 2011; 16(3): 291-296

**P**eroxisome proliferator-activated receptor (PPAR) which is a transcription factor from superfamily of nuclear receptors regulates the expression of genes.<sup>1,2</sup> It is activated by fatty acids, prostanoids, and thiazolidinediones (insulin-sensitizing anti-diabetic agents)<sup>3,4</sup> and plays an important role in regulation of cellular differentiation (adipocyte differentiation), development, metabolism (carbohydrate, lipid, protein), and tumorigenesis.<sup>5</sup> PPAR-gamma (PPAR- $\gamma$ ) is mostly expressed in adipose tissue.<sup>5</sup>

PPAR- $\gamma$  has strong effects on various diseases including osteoporosis,<sup>6,7</sup> atherosclerosis, inflammation, carcinogenesis, type-2 diabetes mellitus, insulin resistance and obesity.

Hereditary disorders mutation in PPAR,

rare gain-of-function mutation (Pro115Gln) and two loss-of-function mutations (Val290Met and Pro467Leu) have been recognized. The first genetic variant that is highly prevalent was Pro12Ala polymorphism which was identified by Yen et al.<sup>8</sup> It is CCA-to-GCA missense mutation which is associated with type-2 diabetes mellitus, insulin resistance and obesity. There are also some reports from Pro12Ala polymorphism effects on the growth of cancer cells.<sup>9,10</sup> This mutation in codon 12 of exon B of the PPAR gene encodes the NH2-terminal residue which defines the adipocyte-specific PPAR- $\gamma$ -2 isoform and decreases the risk of insulin resistance with allele frequency 0.03-0.12 in some populations.<sup>11</sup>

The initial publication reported a 75% risk

<sup>a</sup> Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

<sup>b</sup> Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

\* Corresponding Author

E-mail: negarazarpira@yahoo.com

reduction for diabetes conferred by the Ala allele,<sup>12</sup> and it is said that persons with the Ala12 allele have a reduced risk of colorectal cancer,<sup>13</sup> prostate cancer,<sup>14</sup> endometrial cancer,<sup>15</sup> sporadic colorectal adenoma,<sup>16</sup> gastric cancer,<sup>17</sup> and adenocarcinoma and peptic ulcer disease (PUD).<sup>10</sup>

The rare allele frequencies (Ala) has been reported to range from 2% to 18% in healthy populations,<sup>18</sup> 5.9% to 21.6% (median: 12.7%) in Caucasians, and 1.7% to 9.3% (median: 4.5%) in Eastern Asian descent (Chinese or Japanese).<sup>19</sup> In some studies, the rare allele frequencies are reported 12% in Caucasians, 10% in Native Americans, 8% in Samoans, 4% in Japanese, 3% in African-Americans, 2% in Nauruan people, and 1% in Chinese.<sup>20,21</sup>

Full understanding of distribution and genotype frequency of this polymorphism might have clinical utility. In this study, we analyzed 128 healthy individuals to determine PPAR- $\square$  (Pro12Ala) variants and identify the frequency of alleles in Iranian population.

**Methods**

128 healthy volunteers who were selected from Blood Transfusion Organization were enrolled in this study. In addition, Ethics Committee's approval and participants' consent were obtained. They were selected according to World Health Organization protocol for blood donation including all laboratory and clinical tests with normal parameters.

Peripheral blood was used for isolation of buffy coat (rich source of DNA) with use of Ficoll gradient (Fresenius Kabi Norge AS, Norway). DNA was extracted according to Commercial DNA extraction Kit DNP protocol (DNP Extraction Kit, Sinagen Company, Tehran, Iran). To determine single nucleotide polymorphisms (SNPs), we did real time polymerase chain reaction (RT-PCR), using TaqMan (MetaBion, Germany) allelic discrimi-

nation assays based on the procedure presented by Doney et al with some modifications.<sup>22</sup>

The primer and probes were as:

Pro12 Forward: TCCATGCTGTTATGGGT-GAAACT

Pro12 Reverse: CTTTACCTTGTGATATGTTTGCAGACA

Pro12 Probe (Fam labelled): TCTCCTATT-GACCCAGAAAGCGATTCCCTT

Ala12 Probe (Fam labelled): TCTCCTATT-GACGCAGAAAGCGATTCCCTT

PCR premix consisted of commercial premix (Takara Bio Inc, Japan) with primer and TaqMan probe. Cycling was performed in a real time thermal cycler (BioRad, USA) as:

**Stage 1 (initial denaturation):** 95°C for 10 sec

**Stage 2 (PCR):** 95°C for 5 sec and 60°C for 20 sec. This stage was repeated 45 times.

One product from each genotype was sequenced with ABI sequencer Genetic Analyzer (Applied Biosystems, Foster City, CA) to confirm the results.

Sample size was calculated based on Allel C in European population ( $p = 92.4\%$ ) and  $\alpha = 0.05$  and the result was  $n \geq 108$ . Genotype and Allel frequencies were calculated and the Hardy-Weinberg equilibrium was tested using Arlequin 3.13 software. The frequencies of all genotypes and alleles in our population were compared with other reports. All calculations were done by SPSS statistical package (version 15.0, SPSS) using chi-square and Fisher's exact test. P value  $\leq 0.05$  was considered significant.

**Results**

Allele and genotypes frequencies for PPAR- $\square$  (rs1801282) were deviated from Hardy-Weinberg equilibrium (HWE). HWE was used for checking the normal distribution of these genotypes in our population. Its p value was  $\leq 0.05$  that is not significant. It might be because

**Table 1.** The genotypic characters of studied individuals

Gene	Allelic frequencies n (%)		Genotypic Frequencies n (%)			HWE
	C (Pro)	G (Ala)	CC (Pro/Pro)	CG (Pro/Ala)	GG (Ala/Ala)	
PPAR	238 (92.97)	18 (7.03)	110 (85.94)	18 (14.06)	0	$\leq 0.05$

HWE: Hardy-Weinberg equilibrium,

**Table 2.** A comparison of allelic and genotypic frequencies (Pro12Ala) between Iranian population and others

Population	n	Allele frequencies		Genotype frequencies			P (A)	P (G)	HWE	Ref
		C Pro n (%)	G Ala n (%)	CC Pro/Pro n (%)	CG Pro/Ala n (%)	GG Ala/Ala n (%)				
Iranians (this study)	128	238 (92.97)	18 (7.03)	110 (85.94)	18 (14.06)	0 (0.0)	-	-	$\leq 0.05$	-
Asian	90	176 (97.8)	4 (2.2)	86 (95.6)	4 (4.4)	0 (0.0)	0.018	0.015	1.000	28
Asian	90	170 (94.4)	10 (5.6)	80 (88.9)	10 (11.1)	0 (0.0)	0.341	0.335	-	28
Asian	88	166 (94.3)	10 (5.7)	78 (88.6)	10 (11.4)	0 (0.0)	0.363	0.335	0.752	28
Asian	48	90 (93.8)	6 (6.2)	42 (87.5)	6 (12.5)	0 (0.0)	0.504	0.305	0.752	28
Uygurs	111	196 (89.0)	25 (11.0)	86 (77.0)	25 (23.0)	0 (0.0)	0.071	0.345	Yes	32
Kazaks	80	146 (91.0)	14 (9.0)	66 (83.0)	14 (17.0)	0 (0.0)	0.323	0.295	Yes	32
Hans	102	193 (95.0)	11 (5.0)	91 (90.0)	11 (10.0)	0 (0.0)	0.302	0.057	Yes	32
Hans	180	346 (96.1)	14 (3.9)	166 (92.2)	14 (7.8)	0 (0.0)	0.062	0.234	NM	30
Korea	427	809 (94.7)	45 (5.3)	384 (89.9)	41 (9.6)	2 (0.5)	0.179	0.323	NM	29
Indian	241	424 (88.0)	58 (12.0)	186 (77.2)	52 (21.6)	3 (1.2)	0.021	0.254	Yes	31
African-American	48	92 (95.8)	4 (4.2)	44 (91.7)	4 (8.3)	0 (0.0)	0.234	0.335	1.000	28
African-American	46	88 (95.7)	4 (4.3)	42 (91.3)	4 (8.7)	0 (0.0)	0.263	0.335	1.000	28
African-American	12	24 (100.0)	0 (0.0)	12 (100.0)	0 (0.0)	0 (0.0)	0.335	0.335	NM	28
African-American	1005	1964 (98.0)	46 (2.3)	959 (95.4)	46 (4.6)	0 (0.0)	0.00	0.00	Yes	37
European	44	82 (93.2)	6 (6.8)	38 (86.4)	6 (13.6)	0 (0.0)	0.345	0.345	0.752	28
European	48	84 (93.8)	6 (6.2)	42 (87.5)	6 (12.5)	0 (0.0)	0.876	0.335	0.752	28
European	120	222 (92.5)	18 (7.5)	104 (86.7)	14 (11.7)	2 (1.7)	0.295	0.335	0.251	28
European	118	218 (92.4)	18 (7.6)	102 (86.4)	14 (11.9)	2 (1.7)	0.335	0.335	NM	28
European (Caucasian)	22	40 (90.9)	4 (9.1)	18 (81.8)	4 (18.2)	0 (0.0)	0.335	0.335	0.752	28
French (Caucasian)	318	555 (87.0)	81 (13.0)	246 (77.4)	63 (19.8)	9 (2.8)	0.008	0.046	Yes	34
Ukraine	39	61 (72.6)	17 (27.4)	24 (63.0)	13 (33.0)	2 (4.4)	0.00	0.00	NM	33
Greece	140	266 (32.0)	14 (68.0)	126 (90.0)	14 (10.0)	0 (0.0)	0.335	0.335	Yes	35
Prague Czech	97	152 (79.0)	42 (21.0)	61 (63.0)	30 (31.0)	6 (6.0)	0.00	0.00	NM	36
Sub-Saharan African	120	240 (100.0)	0 (0.0)	120 (100.0)	0 (0.0)	0 (0.0)	0.00	0.00	NM	28

P (A): P value of  $\chi^2$  test between allele frequencies; P (G): P value of  $\chi^2$  test between genotypic frequencies; HWE: Hardy Weinberg equilibrium; NM: Not mentioned

of small sample size, and also same ethnic compositions that could be disappear if random sampling would be done. Also, the accuracy of our method was confirmed by sequencing; indicating decrease of possibilities in personal and instrumental errors.

The allelic frequencies were 0.93 and 0.07 for Pro and Ala, respectively. Distributions of genotypes were 0.86 for Pro/Pro, 0.14 for Ala/Pro and 0.00 for Ala/Ala which is shown in table 1. A comparison of allelic and genotypic frequencies in Iranian population and those in others is shown in table 2.

## Discussion

The first understanding of the importance of PPAR- $\gamma$  in human occurred in 1995, when it was identified as the receptor for the Thiazolidinedione (TZD) insulin-sensitizing drugs.<sup>23</sup> Three potent and highly PPAR- $\gamma$ -selective TZDs as the first new class of insulin-sensitizing agents have been used in large-scale clinical practice to date. Understanding the relation between response to drugs such as Pioglitazone and these SNPs is necessary and may be useful in individualized treatments in clinics. Pro-to-Ala exchange would reduce transcriptional activity of PPAR,<sup>24</sup> and several studies reported possible involvement of Pro12Ala polymorphism in the pathogenesis of insulin resistance, atherosclerosis, adipocyte differentiation, lipid metabolism, inflammation, and malignancy. It may be associated with decreased insulin resistance and decreased risk of type 2 diabetes.

Genotypic frequencies were 85.94% for CC, 14.06% for CG, and 0% for GG and allelic frequencies were 0.93 and 0.07 for C and G, respectively. Comparing allelic and genotypic frequencies of our data with previous reports on several ethnic groups, such as reports from Asians,<sup>25</sup> Indians,<sup>10</sup> African Americans,<sup>26</sup> Sub-Saharan Africans,<sup>25</sup> Frenchs,<sup>27</sup> Ukarians,<sup>28</sup> and Prague Czechs,<sup>29</sup> showed

significant differences.

Five reports from European-Caucasians,<sup>25</sup> Greeks,<sup>30</sup> three reports from Asians, three reports from African Americans,<sup>25</sup> some reports from Hans,<sup>31,32</sup> Uygurs,<sup>32</sup> Koreans,<sup>33</sup> and Kazaks<sup>32</sup> showed no significant differences between our data and their findings.

This gene might be an important thrifty gene. The frequency of the minor alanine allele in Caucasians (0.10) was comparable to the ones previously reported in other Caucasian populations.<sup>34,35</sup> We found significant differences in minor allele frequencies between African Americans (0.04) and American Indians (0.19) compared to Caucasians. In Asians, the frequency of the minor alanine allele differs from 0.022 to 0.062 when compared to our population (0.073); it is deviate from the findings in Asia.

It was also showed that the frequency of the minor alanine allele in Uygurs (11.0) was significantly higher than that in Hans (3.9-5.0).<sup>32</sup> Also There are some controversies between different studies in Europe in minor allele frequencies.<sup>25,27-30</sup>

## Conclusions

Statistical differences in the distribution of the PPAR- $\gamma$ -2 Pro12Ala polymorphism between various populations and Iran showed the importance of studying this SNP as well. Iran is an ethno-linguistically diverse country located on southwest Asia, with 67 million populations. It seems that Iranians are genetically different from some other populations in Asia and other continents. Our study confirms this difference regarding the PPAR- $\gamma$ -2 polymorphism.

## Acknowledgments

This work was financially supported by research grant from Iran University of Medical Sciences and Shiraz University of Medical Sciences. (Grant No. 85/P and P/88-116)

## Conflict of Interests

Authors have no conflict of interests.

### Authors' Contributions

FN was participated in writing the proposal and the manuscript. NA and PRM were contributed in proposal and article writing. All authors have read and approved the content of the manuscript.

### References

1. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. *Pharmacol Rev* 2006; 58(6): 726-41.
2. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. *Endocr Rev* 1999; 20(5): 649-88.
3. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. *J Clin Invest* 2000; 106(4): 467-72.
4. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. *Diabetes* 1996; 45(12): 1661-9.
5. Berger J, Moller DE. The mechanisms of action of PPARs. *Annu Rev Med* 2002; 53: 409-35.
6. Chen G, Lin X, Liang J, Lin L. Relationship between polymorphism of PPAR gamma gene and osteoporosis in aged male. *Bone* 2008; 43: S122.
7. Yue H, He JW, Zhang H, Hu WW, Hu YQ, Li M, et al. No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. *Osteoporos Int* 2010; 21(5): 873-82.
8. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. *Biochem Biophys Res Commun* 1997; 241(2): 270-4.
9. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. *Nat Rev Cancer* 2004; 4(1): 61-70.
10. Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishnani N. Analysis of Pro12Ala PPAR gamma polymorphism and *Helicobacter pylori* infection in gastric adenocarcinoma and peptic ulcer diseases. *Ann Oncol* 2008; 19(7): 1299-303.
11. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. *Mol Endocrinol* 1992; 6(10): 1634-41.
12. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPAR-gamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nat Genet* 1998; 20(3): 284-7.
13. Paltoo D, Woodson K, Taylor P, Albanes D, Virtamo J, Tangrea J. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. *Cancer Lett* 2003; 191(1): 67-74.
14. Paynter RA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. No evidence of a role for PPARgamma Pro12Ala polymorphism in endometrial cancer susceptibility. *Pharmacogenetics* 2004; 14(12): 851-6.
15. Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, et al. The PPAR{gamma} Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas. *Carcinogenesis* 2005; 26(3): 579-85.
16. Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, et al. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, *Helicobacter pylori* infection and non-cardia gastric carcinoma in Chinese. *Aliment Pharmacol Ther* 2006; 23(2): 289-94.
17. Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Maruyama N, et al. Influence of peroxisome proliferator-activated receptor (PPAR)gamma Pro12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese. *Dig Dis Sci* 2007; 53(3): 614-21.
18. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. *Am J Epidemiol* 2005; 162(2): 101-14.
19. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. *Am J Epidemiol* 2010; 171(6): 645-55.
20. Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, et al. Human peroxisome proliferators activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipotrophic diabetes. *Diabetes* 1998; 47(3): 490-2.

21. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. *Diabetes* 2001; 50(4): 891-4.
22. Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, et al. Haplotype analysis of the PPAR $\gamma$  Pro12Ala and C1431T variants reveals opposing associations with body weight. *BMC Genet* 2002; 3: 21.
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). *J Biol Chem* 1995; 270(22): 12953-6.
24. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPAR $\gamma$ 2 associated with decreased receptor activity, lower body mass index, and improved insulin sensitivity. *Nat Genet* 1998; 20(3): 284-7.
25. Rs1801282. [cited 2011 March 6]. Available from URL: <http://www.snpedia.com/index.php/Rs1801282>
26. Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL, et al. Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African Americans: the Atherosclerosis Risk in Communities Study. *Diabetes* 2003; 52(6): 1568-72.
27. Ghousaini M, Meyre D, Lobbens S, Charpentier G, Clément K, Charles MA, et al. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. *BMC Med Genet* 2005; 6: 11.
28. Kaydashev IP, Rasin AM, Shlykova OA, Gorbas' IM, Smirnova IP, Petrushov AV, et al. Frequency of the Pro12Ala-polymorphism of the gene PPAR $\gamma$ 2 in the Ukrainian population and its possible relation to the development of the metabolic syndrome. *Cytol Genet* 2007; 41(5): 298-302.
29. Pintérová D, Cerná M, Kolostová K, Novota P, Cimburová M, Romzová M, et al. The frequency of alleles of the Pro12Ala polymorphism in PPAR $\gamma$ 2 is different between healthy controls and patients with type 2 diabetes. *Folia Biol (Praha)* 2004; 50(5): 153-6.
30. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala Polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. *Hormones (Athens)* 2009; 8(4): 267-72.
31. Fu M, Chen H, Li X, Li J, Wu B, Cheng L, et al. Association of Pro12Ala variant in peroxisome proliferator-activated receptor-gamma2 gene with type 2 diabetes mellitus. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2002; 19(3): 234-8. (Chinese).
32. Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, et al. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uyghur, Kazak and Han subjects. *Clin Exp Pharmacol Physiol* 2008; 35(2): 187-91.
33. Hwang KR, Choi YM, Kim JM, Lee GH, Kim JJ, Chae SJ, et al. Association of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism with advanced-stage endometriosis. *Am J Reprod Immunol* 2010; 64(5): 333-8.
34. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, et al. The common PPAR-gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nat Genet* 2000; 26(1): 76-80.
35. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome poliferator-activated receptor- $\gamma$ 2 Pro12Ala variant: association with type 2 diabetes and trait differences. *Diabetes* 2001; 50: 886-90.